|
|
| | 13,14-Dihydro-15(R)-prostaglandin E1 Basic information |
| Product Name: | 13,14-Dihydro-15(R)-prostaglandin E1 | | Synonyms: | 9-OXO-11ALPHA,15R-DIHYDROXY-PROSTAN-1-OIC ACID;13,14-dihydro-15(R)-PGE1;9-oxo-11α,15R-dihydroxy-prostan-1-oic acid;Prostan-1-oic acid, 11,15-dihydroxy-9-oxo-, (11α,15R)- (9CI);13,14-Dihydro-15(R)-prostaglandin E1 | | CAS: | 201848-10-4 | | MF: | C20H36O5 | | MW: | 356.5 | | EINECS: | | | Product Categories: | | | Mol File: | 201848-10-4.mol |  |
| | 13,14-Dihydro-15(R)-prostaglandin E1 Chemical Properties |
| Boiling point | 541.4±35.0 °C(Predicted) | | density | 1.075±0.06 g/cm3(Predicted) | | solubility | DMF: >100 mg/ml (from PGE1); DMSO: >50 mg/ml (from PGE1); Ethanol: >50 mg/ml (from PGE1); PBS pH 7.2: >1.6 mg/ml (from PGE1) | | pka | 4.77±0.10(Predicted) |
| | 13,14-Dihydro-15(R)-prostaglandin E1 Usage And Synthesis |
| Uses | 13,14-dihydro-15(R)-Prostaglandin E1 (13,14-dihydro-15(R)- PGE1) is an analog of 13,14-dihydro- PGE1 which has the hydroxyl group at C-15 in the unnatural R configuration[1]. | | Definition | ChEBI: 13,14-dihydro-15(R)-Prostaglandin E1 is a prostanoid. | | References | [1] Sinzinger H, et al. PGE1 and 13, 14-dihydro-PGE1 Increase Low-Density Lipoprotein Receptors and Improve Arterial Wall Lipid Metabolism//Prostaglandin E1: New Aspects on Pharmacology, Metabolism and Clinical Efficacy. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991: 39-48. |
| | 13,14-Dihydro-15(R)-prostaglandin E1 Preparation Products And Raw materials |
|